Montelukast asthma drug under review over mental health concerns

Getty/PeopleImages

By Jane Collingwood

Montelukast, a medication regularly prescribed for asthma, is being reviewed by the Medicines and Healthcare products Regulatory Agency (MHRA) after reports of neuropsychiatric reactions including aggression, intrusive thoughts, and suicidal behaviour.

Clinicians should be aware of neuropsychiatric reactions such as sleep disturbances, depression, and agitation, the MHRA previously said.